174 related articles for article (PubMed ID: 19394758)
1. Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-N-acetylgalactosaminidase activity.
Greco M; Mitri MD; Chiriacò F; Leo G; Brienza E; Maffia M
Cancer Lett; 2009 Oct; 283(2):222-9. PubMed ID: 19394758
[TBL] [Abstract][Full Text] [Related]
2. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients.
Mian S; Ugurel S; Parkinson E; Schlenzka I; Dryden I; Lancashire L; Ball G; Creaser C; Rees R; Schadendorf D
J Clin Oncol; 2005 Aug; 23(22):5088-93. PubMed ID: 16051955
[TBL] [Abstract][Full Text] [Related]
3. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
Findeisen P; Zapatka M; Peccerella T; Matzk H; Neumaier M; Schadendorf D; Ugurel S
J Clin Oncol; 2009 May; 27(13):2199-208. PubMed ID: 19307507
[TBL] [Abstract][Full Text] [Related]
4. MIA, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
[TBL] [Abstract][Full Text] [Related]
5. Cluster analysis of serum proteins in malignant cutaneous melanoma: search for disease markers.
Ragazzi E; Vogliardi S; Allegri G; Costa CV; Lise M; Rossi CR; Seraglia R; Traldi P
Rapid Commun Mass Spectrom; 2003; 17(13):1511-5. PubMed ID: 12820221
[No Abstract] [Full Text] [Related]
6. Proteomic analysis of membrane rafts of melanoma cells identifies protein patterns characteristic of the tumor progression stage.
Baruthio F; Quadroni M; Rüegg C; Mariotti A
Proteomics; 2008 Nov; 8(22):4733-47. PubMed ID: 18942674
[TBL] [Abstract][Full Text] [Related]
7. [Profiles of low-molecular proteome spectrum obtained through SELDI-TOF mass spectrometry in the sera of patients with metastatic malignant melanoma: pilot study].
Lakomý R'; Greplová K; Pilný R; Budinská E; Valík D; Poprach A; Nemecek R; Vyzula R
Klin Onkol; 2009; 22(5):228-32. PubMed ID: 19886361
[TBL] [Abstract][Full Text] [Related]
8. [Laboratory markers of melanoma progression].
Bánfalvi T; Edesné MB; Gergye M; Udvarhelyi N; Orosz Z; Gilde K; Kremmer T; Ottó S; Tímár J
Magy Onkol; 2003; 47(1):89-104. PubMed ID: 12704461
[TBL] [Abstract][Full Text] [Related]
9. Serum proteomics of lung adenocarcinomas induced by targeted overexpression of c-raf in alveolar epithelium identifies candidate biomarkers.
Chatterji B; Borlak J
Proteomics; 2007 Nov; 7(21):3980-91. PubMed ID: 17902193
[TBL] [Abstract][Full Text] [Related]
10. Proteomic identification of serum biomarkers for head and neck cancer surveillance.
Gourin CG; Zhi W; Adam BL
Laryngoscope; 2009 Jul; 119(7):1291-302. PubMed ID: 19444892
[TBL] [Abstract][Full Text] [Related]
11. Proteomics analysis of kojic acid treated A375 human malignant melanoma cells.
Nawarak J; Huang-Liu R; Kao SH; Liao HH; Sinchaikul S; Chen ST; Cheng SL
J Proteome Res; 2008 Sep; 7(9):3737-46. PubMed ID: 18630942
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma.
Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U
Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451
[TBL] [Abstract][Full Text] [Related]
13. Proteomics-based identification of alpha1-antitrypsin and haptoglobin precursors as novel serum markers in infiltrating ductal breast carcinomas.
Hamrita B; Chahed K; Trimeche M; Guillier CL; Hammann P; Chaïeb A; Korbi S; Chouchane L
Clin Chim Acta; 2009 Jun; 404(2):111-8. PubMed ID: 19306859
[TBL] [Abstract][Full Text] [Related]
14. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma.
Helfrich I; Edler L; Sucker A; Thomas M; Christian S; Schadendorf D; Augustin HG
Clin Cancer Res; 2009 Feb; 15(4):1384-92. PubMed ID: 19228739
[TBL] [Abstract][Full Text] [Related]
15. High plasma proteasome levels are detected in patients with metastatic malignant melanoma.
Stoebner PE; Lavabre-Bertrand T; Henry L; Guiraud I; Carillo S; Dandurand M; Joujoux JM; Bureau JP; Meunier L
Br J Dermatol; 2005 May; 152(5):948-53. PubMed ID: 15888151
[TBL] [Abstract][Full Text] [Related]
16. Results of the determination of serum markers in patients with malignant melanoma.
Lugović L; Situm M; Buljan M; Poduje S; Sebetić K
Coll Antropol; 2007 Jan; 31 Suppl 1():7-11. PubMed ID: 17469741
[TBL] [Abstract][Full Text] [Related]
17. The contribution of proteomics to the identification of biomarkers for cutaneous malignant melanoma.
Bougnoux AC; Solassol J
Clin Biochem; 2013 Apr; 46(6):518-23. PubMed ID: 23262402
[TBL] [Abstract][Full Text] [Related]
18. Protein profiles in sera of patients with malignant cutaneous melanoma.
Ferrari L; Seraglia R; Rossi CR; Bertazzo A; Lise M; Allegri G; Traldi P
Rapid Commun Mass Spectrom; 2000; 14(13):1149-54. PubMed ID: 10867691
[TBL] [Abstract][Full Text] [Related]
19. Proteomic analysis of uveal melanoma reveals novel potential markers involved in tumor progression.
Zuidervaart W; Hensbergen PJ; Wong MC; Deelder AM; Tensen CP; Jager MJ; Gruis NA
Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):786-93. PubMed ID: 16505008
[TBL] [Abstract][Full Text] [Related]
20. Prognostic utility of serum alpha-N-acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients.
Yamamoto N; Naraparaju VR; Urade M
Cancer Res; 1997 Jan; 57(2):295-9. PubMed ID: 9000571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
